Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis
This exploratory study will be used to identify questions that will be part of a new QoL questionnaire for patients with psoriasis and psoriatic arthritis and to determine the sample size needed for its validation. The new questionnaire will be a global QoL questionnaire which will take into account the impact of both psoriasis and psoriatic arthritis on QoL.
- To evaluate the influence of psoriasis and psoriatic arthritis on patient's answers to QoL questions from DLQI, HAQ, EQ-5D, FACIT-fatigue and SF-36.
- To identify an equal number of questions from DLQI, HAQ, EQ-5D, FACIT-fatigue and SF-36 where answers are mostly influenced either by psoriatic arthritis or by psoriasis.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis|
- There is no primary outcome in this study. See objectives. [ Time Frame: 1 Day ] [ Designated as safety issue: No ]There is no primary outcome in this study. Patients with psoriatic arthritis and psoriasis answer questionnaires on one occasion.
|Study Start Date:||June 2010|
|Study Completion Date:||July 2014|
|Primary Completion Date:||July 2014 (Final data collection date for primary outcome measure)|
40 patients with moderate psoriatic arthritis and moderate psoriasis
40 patients with mild psoriatic arthritis and moderate psoriasis
40 patients with moderate psoriatic arthritis and mild psoriasis
This study will recruit three cohorts of 40 patients each: moderate psoriatic arthritis and moderate psoriasis, mild psoriatic arthritis and moderate psoriasis, moderate psoriatic arthritis and mild psoriasis. Eligible patients will fill the following questionnaires: Dermatology Life Quality Index (DLQI), Health Assessment Questionnaire (HAQ), EQ-5D, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-fatigue) and 36-Item Short Form Health Survey Questionnaire (SF-36). In addition, each patient will be asked on a 4 point Likert scale how much their answer to each question is related to the impact of their skin disease or their psoriatic arthritis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01139918
|Kirk Barber Research|
|Calgary, Alberta, Canada, T2S3B3|
|Winnipeg Clinic Dermatology Research|
|Winnipeg, Manitoba, Canada, R3C 0N2|
|Canada, Newfoundland and Labrador|
|Nexus Clinical Research|
|St John's, Newfoundland and Labrador, Canada, A1A 5E8|
|Hamilton, Ontario, Canada, L8N 1V6|
|Lynderm Research Inc.|
|Markham, Ontario, Canada, L3P 1A8|
|Windsor Clinical Research Inc.|
|Windsor, Ontario, Canada, N8W 5L7|
|Innovaderm Research Inc.|
|Montreal, Quebec, Canada, H2K 4L5|
|Diex Research Sherbrooke east|
|Sherbrooke, Quebec, Canada, J1H 1Z1|
|Clinique Médicale Dr Isabelle Delorme|
|St-Hyacinthe, Quebec, Canada, J2S 6L6|
|Centre de Recherche Dermatologique du Quebec Metropolitain|
|Quebec, Canada, G1V 4X7|
|Principal Investigator:||Robert Bissonnette, MD||Innovaderm Research Inc.|